Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants

On June 11, 2026, Enliven Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 8,933,334 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $37.50 per share (the “Firm Shares”), and, in lieu of Firm Shares to certain investors, pre-funded warrants to purchase 1,733,333 Shares (the “Pre-Funded Warrants”) at a price to the public of $37.499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.001 exercise price for each such Pre-Funded Warrant.